로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Neutralizing antibody > Spike RBD > SAD-S35

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

  • Source
    Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a Spike RBD infected Human and is recombinantly produced from human 293 cells (HEK293)
  • Isotype
    Human IgG1/kappa
  • Specificity
    This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
  • Application
    ELISA, FITC
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20 to -70°C for 12 months in lyophilized state from date of receipt;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Spike RBD SDS-PAGE

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa
 Spike RBD ELISA

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.472 μg/mL (QC tested).

 Spike RBD ELISA

Immobilized SARS-CoV-2 S1 protein, His Tag at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).

 Spike RBD ELISA

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 μg/mL (Routinely tested).

 Spike RBD ELISA

Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody (Cat. No. SAD-S35) was incubated with SARS-CoV-2 pseudotyped virus at 37 °C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37 °C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.

 Spike RBD ELISA

Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. SAD-S35) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD:ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1 mutant and treated with the antibody at increasing concentration. Percent inhibition is calculated based on the OD value.

Bioactivity-SPR
 Spike RBD SPR

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD (A475V), His Tag (Cat. No. SPD-C52Hd) with an affinity constant of 87.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Bioactivity-FACS
 Spike RBD FACS

FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag (Cat. No. SPD-C5259) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S protein RBD used is 5μg/ml. The IC50 is 10.33 μg/ml (Routinely tested).

 Spike RBD FACS

FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Cat. No. S1N-C5257) to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35). The concentration of SARS-CoV-2 S1 protein used is 3ug/ml. The IC50 is 1.352 μg/ml (Routinely tested).

  • Background
    Its been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
  • Clinical and Translational Updates
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

코멘트 (0)


ETD of in-stock products: 4 business days

가격(KRW) : 570,000

가격(KRW) : 4,125,000

보급 및 전시



데이터 테이블 및 파일

DMF 신청
DMF (Drug Master File)

연락처

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

신제품

의문 과 코맨트

This web search service is supported by Google Inc.

totop